argenx SE (NASDAQ:ARGX) Receives $662.83 Average Price Target from Brokerages

argenx SE (NASDAQ:ARGX) has been assigned an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $687.00.

ARGX has been the subject of several research analyst reports. Truist Financial restated a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 14th. William Blair reiterated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Oppenheimer increased their target price on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Finally, Citigroup reiterated an “outperform” rating on shares of argenx in a research note on Friday, February 28th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Brucke Financial Inc. bought a new position in argenx during the 4th quarter worth approximately $412,000. Mackenzie Financial Corp lifted its holdings in argenx by 81.4% during the 4th quarter. Mackenzie Financial Corp now owns 4,449 shares of the company’s stock worth $2,736,000 after buying an additional 1,996 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in argenx during the 4th quarter worth approximately $416,000. Vise Technologies Inc. lifted its holdings in argenx by 6.8% during the 4th quarter. Vise Technologies Inc. now owns 799 shares of the company’s stock worth $491,000 after buying an additional 51 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new position in argenx during the 4th quarter worth approximately $28,510,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Trading Up 1.9 %

NASDAQ ARGX opened at $591.45 on Friday. The company has a market capitalization of $35.94 billion, a PE ratio of -672.10 and a beta of 0.59. The business’s 50-day moving average price is $639.78 and its 200 day moving average price is $595.30. argenx has a twelve month low of $349.86 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities analysts predict that argenx will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.